Meet Pharmatrans SANAQ at IPEC Europe Forum 2026 and talk about future of Co-processed Excipients

Pharmatrans SANAQ is pleased to announce its participation in the IPEC Europe Forum 2026, to be held in Torremolinos, Spain, on February 5, 2026.

Pharmatrans SANAQ, is a Swiss based company leader in the distribution and promotion of innovative excipients and in high-functionality ingredients and expert in cutting-edge formulation solutions for pharmaceutical manufacturing.

The IPEC Europe Forum is a valuable opportunity for networking and knowledge sharing on regulatory developments, market expectations, and best practices.

Do you want to discuss the challenges and opportunities related to CoPEs or explore innovative solutions for your formulations?

In this evolving landscape the pharmaceutical industry is constantly evolving, and with it, regulations to ensure its safety and efficacy.

New guideline European Medicines Agency (EMA) Questions and Answers (Q&A) regarding Co-processed Excipients (CoPEs) used in solid oral dosage forms is generating widespread discussion.

This document (EMA/CHMP/CVMP/QWP/422493/2024, July 2024) aims to provide clarity and harmonization on the dossier requirements for CoPEs, introducing a risk-based approach.

What are Co-processed Excipients (CoPEs) and the EMA’s Risk-Based Approach?

According to the EMA, a Co-processed Excipient (CoPE) is a combination of two or more European Pharmacopoeia (Ph. Eur.) excipients processed together using a physical process (e.g., spray-drying or granulation), without the formation of covalent bonds.

The CoPEs goal is to achieve improved functionalities (e.g., better compaction and/or flowability characteristics) that would not be achievable through simple blending.

At the core of the new EMA Q&A is the categorization of CoPEs based on risk (high, medium, low), determined by factors such as the CoPE’s function in the finished product, its physico-chemical characteristics, and its proportion in the formulation.

With this, the EMA aims to ensure the quality, safety, and efficacy of medicines, guiding innovation towards high standards and the debate has highlighted various perspectives:

• The EMA emphasizes the importance of safety and harmonization, offering a flexible and risk-based approach.
• The Pharmaceutical Industry expresses concern about increased regulatory burden and costs, particularly regarding retroactive application to existing products, which could slow down innovation.
• Excipient Manufacturers note the need for substantial R&D investments to meet detailed documentation requirements and call for greater collaboration.

What does this mean in practice for industry stakeholders and excipient manufacturers; and what are the implications?

Dr Marco Resciniti, Technical and Marketing Head at Pharmatrans SANAQ, will be available for meetings to discuss technical topics and collaboration opportunities.

He is now accepting advance meeting requests for the event.

Don’t miss the opportunity to engage with industry experts and discuss how the new EMA guidelines will impact drug product development and manufacturing and the Pharmatrans SANAQ solutions.

To request a meeting with Marco Resciniti during the IPEC Europe Forum 2026, please send an email to [email protected]  or visit https://events.ipec-europe.org/ipec-europe-excipients-forum/ for more information about the event.

We look forward to meeting you in Torremolinos to discuss the future of excipients together!

About Pharmatrans-SANAQ

Founded in 1982 and headquartered in Allschwil, near Basel, Switzerland, Pharmatrans SANAQ AG is a premier pharmaceutical distributor specializing in the marketing and promotion of high-quality excipients and innovative active pharmaceutical ingredients (APIs). We offer extensive formulation expertise to provide our global customers with a complete portfolio of technical and smart solutions for pharmaceutical formulation development and the efficient manufacture of solid and semisolid dosage forms.

Pharmatrans SANAQ delivers innovative solutions built on the foundation of our safe analytical and quality (SANAQ®) approach. We leverage decades of industry experience, deep industrial know-how, strong regulatory skills, strategic partnerships with leading R&D centers, collaborations with international universities, and proven in-house expertise. Our dedicated team of formulation scientists provides comprehensive support across the entire excipients field, from basic raw materials to ready-made products and customized solutions tailored to specific client needs.

Our comprehensive product portfolio includes a wide range of specialized pharmaceutical excipients and active pharmaceutical ingredients (APIs). Key excipients offered by Pharmatrans SANAQ include microcrystalline cellulose (MCC), tartaric acid pellets (TAP), sugar spheres, Mannitol pellets and advanced co-processed excipients.

Pharmatrans is also committed to developing specific tailored products based on unique customer requirements, advanced process technology, and diverse application needs. To achieve this, we collaborate closely with an international network of advanced, carefully selected, and qualified CMO (Contract Manufacturing Organization) and CDMO (Contract Development and Manufacturing Organization) partners, many of whom hold significant international and local process patents.

For further information on our pharmaceutical excipients, formulation development services, API solutions, or to learn more about our SANAQ approach to quality, please visit: www.pharmatrans-sanaq.com